Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro

Pharmacological Research

Volumn 45, Issue 2, 2002, Pages 147-154

  Zelvyte, Inga ^a   Dominaitiene, Ruta ^a   Crisby, Milita ^a,b   Janciauskiene, Sabina ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MAS   (Sweden)

Author keywords

Inflammation; Lipid metabolism; PPARs; Pravastatin; Pro inflammatory molecules

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODINE 125; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; MONOCYTE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT;

EID: 0036445650     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0922     Document Type: Article

References (42)

1. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
2. Ma PT, Gil G, Sudhov TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986; 83: 8370-4.
3. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.
4. Bocan TM, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth BD et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation. Atherosclerosis 1994; 111: 127-42.
5. Faggiotto A, Paoletti R. State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
6. Carvalho AC, Colman RW, Lees RS. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia. Circulation 1974; 50: 570-4.
7. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996; 347: 305-7.
8. Wheeler DC. Are there potential non-lipid-lowering uses of statins? Drugs 1998; 56: 517-52.
9. Kendall MJ, Toescu V. Non-lipid properties of statins. J Clin Pharm Ther 1999; 24: 3-5.
10. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40: S15-18.
11. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 5: 115-20.
12. Owen K, Pick CR, Libretto SE, Adams MJ. Toxicity of a novel HMG-CoA reductase inhibitor in the common marmoset (Callithrix jacchus). Hum Exp Toxicol 1994; 13: 357-68.
13. Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies. Br J Clin Pharmacol 1994; 38: 513-9.
14. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J, Hosokawa T, Tamura A. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938-44.
15. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
16. Crisby MG, Fredriksson-Nordin G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques. Implications for plaque stabilisation. Circulation 2001; 103: 926-33.
17. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 3: 225-32.
18. Brand K, Page S, Rogler G, Bratsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-22.
19. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
20. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
21. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67: 863-76.
22. Janciauskiene S, al Rayyes O, Floren CH, Eriksson S. Low density lipoprotein catabolism is enhanced by the cleaved form of alpha-1-antitrypsin. Scand J Clin Lab Invest 1997; 57: 325-35.
23. Dichtl W, Moraga F, Ares MP, Crisby M, Nilsson J, Lindgren S, Janciauskiene S. The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human monocytes. Mol Cell Biol Res Commun 2000; 4: 50-61.
24. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164-76.
25. Brown G, Zhao X-Q, Sacco DE. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
26. Palinski W. Immunomodulation: A new role for statins? Nat Med 2000; 6: 1311-2.
27. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J, Hosokawa T, Tamura A. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938-44.
28. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
29. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999; 100: 230-5.
30. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410: 83-92.
31. Fruscella P, Romano M, Albani D, Bernasconi S, Luini W, Bruno A, Salmona M, Diomede L. Inhibition of HMG-CoA reductase activity by hypercholesterolaemia reduces leukocyte recruitment and MCP-1 production. Cytokine 2000; 12: 1100-3.
32. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
33. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996; 97: 1535-44.
34. Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies. Br J Clin Pharmacol 1994; 38: 513-9.
35. Luster AD. Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45.
36. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
37. Egashira K et al.. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: Blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J 2000; 14: 1974-8.
38. Romano M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095-100.
39. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-40.
40. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984; 74: 1890-4.
41. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
42. Corton JC, Anderson AP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. 2000; 40: 491-518.